These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 22830345)

  • 41. Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.
    Rampal RK; Pinzon-Ortiz M; Somasundara AVH; Durham B; Koche R; Spitzer B; Mowla S; Krishnan A; Li B; An W; Derkach A; Devlin S; Rong X; Longmire T; Eisman SE; Cordner K; Whitfield JT; Vanasse G; Cao ZA; Levine RL
    Clin Cancer Res; 2021 Jun; 27(12):3456-3468. PubMed ID: 33782031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
    Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
    Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
    [No Abstract]   [Full Text] [Related]  

  • 45. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.
    Mesa RA
    IDrugs; 2010 Jun; 13(6):394-403. PubMed ID: 20506062
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
    Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
    Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms.
    Petiti J; Lo Iacono M; Rosso V; Andreani G; Jovanovski A; Podestà M; Lame D; Gobbi M; Fava C; Saglio G; Frassoni F; Cilloni D
    J Cell Mol Med; 2020 Sep; 24(18):10978-10986. PubMed ID: 32790151
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapy for myeloproliferative neoplasms: when, which agent, and how?
    Geyer HL; Mesa RA
    Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
    Coltro G; Loscocco GG; Vannucchi AM
    Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Practical management of patients with myelofibrosis receiving ruxolitinib.
    Harrison C; Mesa R; Ross D; Mead A; Keohane C; Gotlib J; Verstovsek S
    Expert Rev Hematol; 2013 Oct; 6(5):511-23. PubMed ID: 24083419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
    Verstovsek S; Mesa RA; Livingston RA; Hu W; Mascarenhas J
    J Hematol Oncol; 2023 Jul; 16(1):82. PubMed ID: 37501130
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ruxolitinib for the treatment of patients with polycythemia vera.
    Kiladjian JJ; Winton EF; Talpaz M; Verstovsek S
    Expert Rev Hematol; 2015 Aug; 8(4):391-401. PubMed ID: 25980454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Momelotinib for the treatment of myelofibrosis.
    Xu L; Feng J; Gao G; Tang H
    Expert Opin Pharmacother; 2019 Nov; 20(16):1943-1951. PubMed ID: 31450973
    [No Abstract]   [Full Text] [Related]  

  • 56. [What's new in myeloproliferative neoplasia?].
    Schmidt S; Wolf D
    Dtsch Med Wochenschr; 2022 Mar; 147(6):306-311. PubMed ID: 35291035
    [TBL] [Abstract][Full Text] [Related]  

  • 57. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
    Bose P; Verstovsek S
    Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.
    Masarova L; Bose P; Verstovsek S
    Curr Hematol Malig Rep; 2019 Aug; 14(4):310-327. PubMed ID: 31228096
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
    Wang JC; Kundra A; Andrei M; Baptiste S; Chen C; Wong C; Sindhu H
    Leuk Res; 2016 Apr; 43():39-43. PubMed ID: 26943702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ruxolitinib for the treatment of myelofibrosis.
    Ostojic A; Vrhovac R; Verstovsek S
    Drugs Today (Barc); 2011 Nov; 47(11):817-27. PubMed ID: 22146225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.